Global Stem Cells Group (GSCG), a leading provider of regenerative medicine solutions, is proud to announce its participation in the IV Jornadas de Actualización Medestética 2023 through the International Society for Stem Cell Association (ISSCA), its educational division and also with its line of Cellgenic Exosomes products.
The congress, which will take place on March 30th and 31st at Paseo La Plaza in Buenos Aires, Argentina, will provide a platform for ISSCA to share its knowledge and expertise in regenerative medicine with the Argentine medical community.
ISSCA is a multidisciplinary community of physicians and scientists whose mission is to advance the science, technology, and practice of regenerative medicine to treat disease and lessen human suffering. The organization has been at the forefront of promoting excellent and standardized regenerative medicine and will continue to participate in similar medical events such as this one.
The Global Stem Cells Group will also have a booth at the event to showcase its products, Cellgenic Exosomes, in its two presentations: “Cellgenic Lyophilized Exosomes” and “Cellgenic Flow Exosomes.” Additionally, it will provide guidance on how to use the products on patients.
As part of the program, ISSCA faculty members will be giving presentations and holding practical workshops to demonstrate the latest applications of regenerative medicine. The ISSCA program will cover all aspects of regenerative medicine including guidelines and clinical protocols.
“We are excited to take part in this congress and share our expertise, knowledge, and cellgenic exosome product line with the Argentine medical community,” said Benito Novas, Managing Director of Global Stem Cells Group and Head of Public Relations for the International Society for Stem Cell Application from the USA.
The IV Jornadas de Actualización Medestética 2023 will feature various ISSCA-certified doctors and experts as speakers, including:
Dr. Silvina Pastrana
Dr. Pastrana heads the ISSCA chapter in Argentina and serves as the medical center’s director. “Traditional, advanced, and cutting-edge anti-aging and rejuvenation medicine” will be her theme at this congress. Dr. Silvina will deliver a 40-minute summary of all the regenerative medicine and cell therapies that are now being used to postpone aging and enhance quality of life. therapies using NK cells, fluid and lyophilized exosomes, allogenic therapies, and autologous cells.
Dr. Andrea Lapeire
Dr. Lapeire is a doctor of aesthetic medicine with advanced degrees in environment, homotoxicology, biological medicine, and obesity. She will speak on alopecias: traditional and cutting-edge. Exosome Use and Biological Stimulation Fundamentals.
Prof. Dr. Julio Ferreira
Professor Ferreira is from Argentina and is a professional cosmetic surgery and aesthetic medicine expert. He is a university professor of medicine and is the president of the South American Academy of Aesthetic Surgery. He will cover regenerative therapies in rejuvenation and facial harmonization in his lecture.
Dr. Alfonso Ciancaglini
A specialist in Medical Clinic and regenerative medicine, Dr. Alfonsoi is a member of the International Society For Cellular Therapy Application and holds a certification from the Stem Cells Group. His presentation will discuss the use of regenerative medicine to treat venous ulcers.
Benito Novas is the Head of Public Relations for the International Society for Stem Cell Application from the USA. He is the senior marketing consultant and founder of “Estética marketing INC” as an Author, he has authored several books among them: Su clinica este’tica. Lo que dicen sus pacientes” Marketing Digital en su Clinica Estetica” and “Marketing en Tiempos de Crisis” for more information on Novas you can check on www.benitonovas.com. In this congress. Benito Novas will be covering Digital Marketing in Cash-based practices.
ISSCA at Global Perspective.
ISSCA has been at the forefront of promoting excellent and standardized regenerative medicine. For more information and updates. visit us at https://www.issca.us/
The ISSCA is a multidisciplinary community of physicians and scientists with a mission to advance the science, technology, and practice of Regenerative Medicine to treat disease and lessen human suffering. Its members are leaders in setting standards and promoting excellence in regenerative medicine, related education, certification, research and publications.
About Global Stem Cell Group
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.